Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
Kun Wang, Xiaoyong Dai, Albert Cheung Hoi Yu, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 137
Peptide-functionalized, -assembled and -loaded nanoparticles in cancer therapy
Jingyuan Dai, Milad Ashrafizadeh, Amir R. Aref, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 103981-103981
Closed Access | Times Cited: 57
FOXM1: A small fox that makes more tracks for cancer progression and metastasis
Md Arafat Khan, Parvez Κhan, Aatiya Ahmad, et al.
Seminars in Cancer Biology (2023) Vol. 92, pp. 1-15
Open Access | Times Cited: 53
Current research status of anti-cancer peptides: Mechanism of action, production, and clinical applications
Raj Kumar Chinnadurai, Nazam Khan, Gautam Kumar Meghwanshi, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 114996-114996
Open Access | Times Cited: 39
Targeting the undruggables—the power of protein degraders
Chao Zhang, Yongbo Liu, Guangchen Li, et al.
Science Bulletin (2024) Vol. 69, Iss. 11, pp. 1776-1797
Open Access | Times Cited: 18
A novel peptide CP29L, selected from the phage displayed cyclic random heptapeptide library, demonstrates its potent inhibitory effects to liver cancer HCCLM3 cells by targeting FOXM1
Xinyi Hua, Kun Xiang, Anping Liang, et al.
European Journal of Pharmacology (2025), pp. 177246-177246
Closed Access | Times Cited: 1
FOXM1 promotes malignant biological behavior and metabolic reprogramming by targeting SPINK1 in hepatocellular carcinoma and affecting the p53 pathway
Xu Ding, Jinjun Shi, Zhengqing Lei, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025), pp. 167673-167673
Closed Access | Times Cited: 1
Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer
Benita S. Katzenellenbogen, Valeria Sanabria Guillen, John A. Katzenellenbogen
Breast Cancer Research (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 36
Targeting Peptides: The New Generation of Targeted Drug Delivery Systems
Biagio Todaro, Elisa Ottalagana, Stefano Luin, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1648-1648
Open Access | Times Cited: 31
Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy
Ruoxi Sang, Renming Fan, Aohua Deng, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8464-8483
Closed Access | Times Cited: 27
The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
Bo Hou, Ting Chen, He Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 9
A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy
Bohan Ma, Donghua Liu, Zhe Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 12, pp. 10336-10349
Closed Access | Times Cited: 6
A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt/β-catenin and modulates the immune cells
Chunyan Feng, Albert Cheung Hoi Yu, Zhongfu Wang, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 5
Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system
Hanshu Xie, Chao Zhang
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116168-116168
Closed Access | Times Cited: 5
PROTAC: Novel degradable approach for different targets to treat breast cancer
Zhenjie Wang, Siyao Che, Zhiqiang Yu
European Journal of Pharmaceutical Sciences (2024) Vol. 198, pp. 106793-106793
Open Access | Times Cited: 5
The transcription factor FOXQ1 in cancer
Stefan Koch
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 1
Open Access
Landscape of metabolic alterations and treatment strategies in breast cancer
Xiujuan Wu, Xuanni Tan, Yangqiu Bao, et al.
Genes & Diseases (2025), pp. 101521-101521
Open Access
Role of Ubiquitination-driven Metabolisms in Oncogenesis and Cancer Therapy
Dongqin Yang, Can Yang, Linlin Huang, et al.
Seminars in Cancer Biology (2025)
Closed Access
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging
Hui Fang, Eunsun Yu, Chang Liu, et al.
Seminars in Cancer Biology (2025) Vol. 111, pp. 1-15
Closed Access
Evaluation of the Efficacy of Proline Rich VPPPVPPRRR Peptide (VPP) in MCF-7 Cells
Ziyşan Buse Yaralı Çevik, Berk Buğra Sönmez, Ozan Karaman
International Journal of Peptide Research and Therapeutics (2025) Vol. 31, Iss. 3
Closed Access
Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
Rui Li, Miao Liu, Zhenya Yang, et al.
Molecules (2022) Vol. 27, Iss. 24, pp. 8828-8828
Open Access | Times Cited: 26
Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques
Siyu Chen, Jingliang Cui, Haiyan Chen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115911-115911
Closed Access | Times Cited: 14
Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatments
Sanjeev Raghuwanshi, Andrei L. Gartel
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 189015-189015
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top